Mesoblast Limited · ASX:MSB
Mesoblast — Shareholder Meeting (November 2006)
24 slides from Mesoblast's shareholder meeting presentation, Nov 23, 2006
Slide 1: Regenerative medicine...today's reality
nN ii! mesoblast the edult stem cell company Regenerative medicine...today’s reality November 23, 2006
Slide 2: a mesoblast
a mesoblast
Slide 3: mesoblast
4 mesoblast
Slide 4: A mesoblast
A mesoblast
Slide 5: pmesoblast
a pmesoblast
Slide 6: Research
a pmesoblast io RESEARCH
Slide 7: pmesoblast
pmesoblast ™ carrier alone | © carrier + 225M MPC
Slide 8: pmesoblast
pmesoblast
Slide 9: Femur resection model
» 25-30% of the mid portion of the femur is resected. * Struciural stability maintained by intamedullary nail locked proximally and distally by transiixing screws.
Slide 10: a mesoblast
a mesoblast Cratto-caudil (AP)
Slide 11: pimesoblast
pimesoblast
Slide 12: Human MPC Induce Endogenous Cardiac Arteriogenesis And Improve Cardiac Function After Acute Ischemia
Human MPC Induce Endogenous Cardiac Arteriogenesis And Improve Cardiac Function After Acute Ischemia 4x108 MPC + 0.2x108 MPC 1x10° MNC (MPC-Depleted) % Change in FS baseline 2weeks 2 Ge = Be SS es Se =e zs oe a es oO & oS aS ¢ Zz saline 0.2x10° 1x10° MPC MPC
Slide 13: STUDY I: Allogeneic MPC in Acute Cardiac Ischemia
STUDY I: Allogeneic MPC in Acute Cardiac Ischemia perfusion Measurements By Regional, Direct Injection oe - Allogeneic sheep MPC 25-225 million MPC No immunosuppression Safety and efficacy outcome ea ee per-infarct region measurements and borderzone __
Slide 14: Allogeneic MPC Selectively Enhance Long-Term Perfusion In Infarct Region
Allogeneic MPC Selectively Enhance Long-Term Perfusion In Infarct Region WW controls pd 25M MPC 5M MPC 1) 225M MPC | 450M MPC ost ss Se o 2 2 oe 38 ao oy BE oo: &e 26 2s ~ a o 8 § 2¢ B37 So oid £o 2e aod oOo Zo £ infarct region
Slide 15: Epicardial Injection Of Allogeneic MPC Protects Against Left Ventricular Diastolic Enlargement
Epicardial Injection Of Allogeneic MPC Protects Against Left Ventricular Diastolic Enlargement controls 25M MPC 75M MPC | 225M MPC 450M MPC o c = o a s =_ = S & ml ° = al s = o z S = oS & ~
Slide 16: Allogeneic MPC Treatment Prevents Late Remodelling And Heart Failure
Allogeneic MPC Treatment Prevents Late Remodelling And Heart Failure Associated With Larger Infarct Size ¢ Control H Cells me=|inear (Ce me|inear (Co oe 4 = o wm 8 = = a 4 2 eS oo 7 s rt g - a ° = 3 a4 Normalized infarct size (IL/DL)
Slide 17: STUDY II: Allogeneic MPC in Acute Cardiac Ischemia
STUDY II: Allogeneic MPC in Acute Cardiac Ischemia 5 days post-reperfusion isotope study for function and volume | -Tj * s : : | : ided cathet : By Catheter-Directed Injection, a Allogeneic sheep MPC balloon r _ 225 million MPC | occlusion : No immunosuppression oo Se Ve Safety and efficacy outcome
Slide 18: Allogeneic MPC Prevent Late Cardiac Dysfunction When Injected Endomyocardially
Allogeneic MPC Prevent Late Cardiac Dysfunction When Injected Endomyocardially 5 Days Post-AMI/Reperfusion *p=0.039 | I 225M MPCs —. ) a, ; \ ¥ $0 u a cet — I o e ey Pe: a —) § z Oe a = | EI Eck o A a Se ~
Slide 19: pmesoblast
pmesoblast
Slide 20: MPCs Increase Perfusion In A Patient With Chronic Ischemia
MPCs Increase Perfusion In A Patient With Chronic Ischemia _ baseline Apex -> Base Sixmonths [| : ‘post-MPC — ao 28 | injection gntal Long Aas
Slide 21: MPCs Induce New Bone Growth And Union In A Patient With Femoral Fracture
s ‘ & ONFIDENTE: iL oe a pimesoblast MPCs Induce New Bone Growth And Union nA Patient With Femoral Fracture And Non-Union After 9 Vionths baseline 6 wks post-MPC 12 wks post-MPC implantation implantation
Slide 22: mesoblast
4 mesoblast
Slide 23: pmesoblast |__
pmesoblast |__
Slide 24: Regenerative medicine...the future
nN ii! mesoblast the edult stem cell company Regenerative medicine...the future November 23, 2006